Pomona, New York — February 19, 2025 — NeuroLight, Inc., a pioneering neuromodulation medical device company, today announced the appointment of Jeffry B. Lansman, Ph.D. to its Advisory Board. Dr. Lansman is a Professor Emeritus of Cellular & Molecular Pharmacology in the School of Medicine, University of California, San Francisco.
NeuroLight is developing breakthrough brain sensory stimulation technology enabling the transfer of therapeutic neural states between individuals. Neuromodulation shows promise for treating insomnia, neurodegeneration, affective states, and enhancing cognition, learning, and performance.
Dr. Lansman brings expertise in biophysics and cellular neuroscience to NeuroLight’s Advisory Board. He is credited with identifying neuronal calcium channels, their role in signal processing and pharmacological modulation. During his distinguished career, he has published more than sixty peer-reviewed papers and served on the editorial boards of several professional journals. He currently serves as Founder and CEO of AI-Life, which develops AI-powered precision cardiovascular diagnostics.
“Dr. Lansman’s pioneering work in neuroscience and biophysics makes him an invaluable addition to our Advisory Board,” said Alexander Poltorak, NeuroLight’s Founder and President. “His expertise will be crucial as we develop transformative solutions for sleep and cognitive performance.”
“Direct neuromodulation is a powerful approach for treating disorders of the brain without drugs,” said Dr. Lansman. “I am pleased to join NeuroLight’s Advisory Board as the company pioneers groundbreaking technology to transfer brain states via precise multimodal sensory stimulation.”
